Partners to Establish Center for Medical Cannabis R&D in Israel

Two Israeli-based biotechnology firms have agreed to establish a center to concentrate research, development, and commercialization of medical marihuana and other cannabis products.

The partners are iCAN- Israel Cannabis (Beit Shemesh, Israel) and Breath of Life Pharma (BOL Pharma; Israel). BOL Pharma, established in 2008, is regarded as Israel’s leading medical cannabis drug development firm, while iCAN- Israel Cannabis is actively engaged in identifying and accelerating cannabis technologies in Israel.

The primary objectives of the new center will be to strengthen research and development of new cannabis-related technologies with the goal of successful commercialization. The center will serve as an incubator for cannabis innovation as well as a validator of cannabis-based medicines and agricultural-technological and topical product development based on stringent guidelines and standards.

Dr. Tamir Gedo, CEO of BOL Pharma, said, “BOL greenhouses allow developers to use the professional services and knowledge of BOL Pharma, in order to produce strains, improve growing conditions, master extraction, formulation, and production of materials under GMP conditions, and ultimately to enable companies to commercialize their research and go to market. Together with iCAN- Israel Cannabis, we will incubate companies from all over the world to test and validate medical products for the global cannabis market.”

Saul Kaye, CEO of iCAN- Israel Cannabis, said “We are thrilled to partner with BOL Pharma and provide a global incubator and proving ground for cannabis technology. We are confident our partnership will enable the most promising start-ups and innovators in Israel and abroad, to create world class products for the global cannabis economy.”

Related Links:
iCAN- Israel Cannabis
Breath of Life Pharma